Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Review Special Issue Series—Measuring Neutralizing Antibody Responses against SARS-CoV-2 and...
share announcement

Review Special Issue Series—Measuring Neutralizing Antibody Responses against SARS-CoV-2 and Emerging Infectious Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 1130

Special Issue Editor

Dr. Ruth Harvey

E-Mail
Guest Editor
The Francis Crick Institute, London, UK
Interests: Influenza; SARS-CoV-2; serology; vaccines; clinically relevant; animal-human interface

Special Issue Information

Dear Colleagues 

As the guest editor, I am pleased to announce the Special Issue “Measuring Neutralizing Antibody Responses against SARS-CoV-2 and Emerging Infectious Diseases”, in which we aim to encourage more submissions of review papers. Please note the following instructions:

  1. The word count should be more than 3000 words in the main text;
  2. Manuscripts must cite the newest published research;
  3. Manuscripts must comprehensively summarize the current hot topics. 

Vaccines will provide full support for long reviews (5000 or more words in the main text) of high quality. For more detailed information, please do not hesitate to contact the Vaccines Office: vaccines@mdpi.com.

Dr. Ruth Harvey
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • neutralizing
  • antibody
  • infectious
  • diseases

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1289 KiB  
Article
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial
by Jihai Tang, Qinghua Xu, Chaoyin Zhu, Kun Xuan, Tao Li, Qingru Li, Xingya Pang, Zhenqiu Zha, Jinwei Li, Liyang Qiao, Haiyang Xu, Gang Wu, Yan Tian, Jun Han, Cuige Gao, Jiang Yi, Gui Qian, Xuxin Tian and Liangzhi Xie
Vaccines 2024, 12(2), 175; https://doi.org/10.3390/vaccines12020175 - 08 Feb 2024
Viewed by 837
Abstract
The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become the dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its immunogenicity against Omicron EG.5, comparing it [...] Read more.
The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become the dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its immunogenicity against Omicron EG.5, comparing it with its progenitor vaccine, SCTV01E (NCT05933512). As of 12 September 2023, 429 participants aged ≥18 years were randomized into the groups SCTV01E (N = 215) and SCTV01E-2 (N = 214). Both vaccines showed increases in neutralizing antibody (nAb) against Omicron EG.5, with a 5.7-fold increase and a 9.0-fold increase in the SCTV01E and SCTV01E-2 groups 14 days post-vaccination, respectively. The predetermined statistical endpoints were achieved, showing that the geometric mean titer (GMT) of nAb and the seroresponse rate (SRR) against Omicron EG.5 were significantly higher in the SCTV01E-2 group than in the SCTV01E group. Additionally, SCTV01E and SCTV01E-2 induced a 5.5-fold and a 5.9-fold increase in nAb against XBB.1, respectively. Reactogenicity was generally mild and transient. No vaccine-related serious adverse events (SAEs), adverse events of special interest (AESIs), or deaths were reported. In summary, SCTV01E-2 elicited robust neutralizing responses against Omicron EG.5 and XBB.1 without raising safety concerns, highlighting its potential as a versatile COVID-19 vaccine against SARS-CoV-2 variants. Full article
(This article belongs to the Special Issue Review Special Issue Series—Measuring Neutralizing Antibody Responses against SARS-CoV-2 and Emerging Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop